Interpretation of the updated position statements on bariatric surgery and implantable devices from American Society for Metabolic and Bariatric Surgery in 2016
SHEN Xiao-jun
ZHENG Cheng-zhu
YIN Kai
Abstract：The American Society for Metabolic and Bariatric Surgery (ASMBS) has issued a series of position statements in April 2016 in response to numerous inquiries made to the Society by patients, physicians, hospitals, the media, and others regarding the metabolic and bariatric surgery and two kinds of implantable devices. Data suggest that metabolic and bariatric surgery may improve survival and longevity, relative to the nonsurgical usual care treatment of individuals with class Ⅱ and Ⅲ obesity. The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) provided an overview of the available evidence regarding the clinical utility, efficacy, and safety of endoscopically placed intragastric balloon for obesity and related diseases. The technology of intragastric balloons and its application in the treatment of obesity were approved by ASMBS and SAGES. A new device for weight loss called vagal blocking therapy for obesity (VBLOC) was approved for patients with a body mass index (BMI) 35 to 45 kg/m2. Based on current evidence available, the long-term efficacy and adverse events of this new technology should be further established.
Keywords：obesitymetabolic and bariatric surgeryintragastric balloonvagal blocking therapy
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 18-20 )